Expert Guidance on Optimizing Treatment Selection, Sequencing, and Safety for Veterans with Later-Line Metastatic Colorectal Cancer Treated at the Veteran’s Health Administration
PROGRAM CHAIR
Shubham Pant, MD, MBBS
Professor, Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, TX
PROGRAM OVERVIEW
This engaging educational activity is designed for VA clinicians involved in evaluating and managing veterans with metastatic colorectal cancer (mCRC). The program presents real-world evidence through didactic presentation, case-based discussions, animations, along with podcasts featuring key opinion leaders. Learn to differentiate among evolving agents in the third line (3L) treatment setting for patients with refractory mCRC; Identify patientspecific factors and prior therapies to guide optimal sequencing of 3L mCRC therapies; and utilize dose escalation strategies and proactive management of adverse events (AEs) to mitigate potentially treatment-limiting toxicities and prolong 3L treatment duration for Veterans with mCRC.
TARGET AUDIENCE
This activity is designed to meet the educational needs of VA clinicians involved in the evaluation and management of veterans with mCRC including, but not limited to medical oncologists, gastroenterologists, and advanced practice providers (APPs) such as oncology nurses, nurse practitioners, pharmacists, and physician assistants.
LEARNING OBJECTIVE
Upon the completion of this program, attendees should be able to:
- Explain the therapeutic potential and differentiate among available third-line (3L) treatment options for Veterans with metastatic colorectal cancer (mCRC)
- Leverage expert insight, real-world evidence (RWE), treatment histories, and patient-specific factors to inform optimal treatment selection and sequencing of 3L mCRC therapies
- Utilize alternative dosing and proactive adverse event (AE) management strategies to mitigate potentially treatment-limiting toxicities and prolong 3L treatment duration for Veterans with mCRC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Shubham Pant, MD | Dr. Pant discloses serving as a consultant for Zymeworks, Ipsen, Novartis, Janssen, Boehringer Ingelheim, AskGene Pharma, BPGbio, Jazz Pharmaceuticals, and AstraZeneca. He additionally receives research funding for clinical trials paid directly to The University of Texas MD Anderson Cancer Center from Mirati Therapeutics, Lilly, Xencor, Novartis, Bristol Myers Squibb, Astellas Pharma, Framewave, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics, Biotech, Pfizer, and Telperian. He also discloses ownership interest in Telperian. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Anita Misra-Press, PhD, Medical Director of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Brianna Hefele, PA-C, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.
The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: February 28, 2025
EXPIRATION DATE: February 28, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Shubham Pant, MD, MBBS
Professor, Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, TX
FACULTY PRESENTER
Jonathan Mizrahi, MD
Gastrointestinal Medical Oncologist
Ochsner MD Anderson Cancer Center
New Orleans, LA
PROGRAM OVERVIEW
This podcast is designed for VA clinicians involved in evaluating and managing veterans with metastatic colorectal cancer (mCRC), including, but not limited to, medical oncologists, gastroenterologists, and advanced practice providers (APPs) such as oncology nurses, nurse practitioners, pharmacists, and physician assistants. Specifically, this podcast will highlight adverse events (AEs) specifically associated with the approved treatment options for refractory mCRC in 3L setting and discuss new strategies, such as dose-escalation and proactive management of AEs to mitigate potentially treatment-limiting toxicities and prolong 3L treatment duration for Veterans with mCRC.
TARGET AUDIENCE
This activity is designed to meet the educational needs of VA clinicians involved in the evaluation and management of veterans with mCRC including, but not limited to medical oncologists, gastroenterologists, and advanced practice providers (APPs) such as oncology nurses, nurse practitioners, pharmacists, and physician assistants.
LEARNING OBJECTIVE
Upon the completion of this program, attendees should be able to:
- Utilize alternative dosing and proactive adverse event (AE) management strategies to mitigate potentially treatment-limiting toxicities and prolong 3L treatment duration for Veterans with mCRC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Shubham Pant, MD | Dr. Pant discloses serving as a consultant for Zymeworks, Ipsen, Novartis, Janssen, Boehringer Ingelheim, AskGene Pharma, BPGBio, Jazz Pharmaceuticals, and AstraZeneca. He additionally receives research funding for clinical trials paid directly to The University of Texas MD Anderson Cancer Center from Mirati Therapeutics, Lilly, Xencor, Novartis, Bristol Myers Squibb, Astellas Pharma, Framewave, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics, Biotech, Pfizer and Telperian. He also discloses ownership interest in Telperian. |
| Jonathan Mizrahi, MD | Dr. Mizrahi discloses serving as a consultant for Exelixis, AstraZeneca, Amgen, and Intera Oncology. He also discloses being on speaker’s bureaus for Exelixis, AstraZeneca, and Bristol Myers Squibb. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, Wolters Kluwer (UpToDate author royalties).
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Anita Misra-Press, PhD, Medical Director of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: December 17, 2024
EXPIRATION DATE: December 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Shubham Pant, MD, MBBS
Professor, Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, TX
FACULTY PRESENTER
Benjamin Leon Musher, MD
Dan L Duncan Comprehensive Cancer Center
Professor of Medicine
Baylor College of Medicine
Houston, TX
PROGRAM OVERVIEW
This podcast is designed for VA clinicians involved in evaluating and managing veterans with mCRC, including, but not limited to, medical oncologists, gastroenterologists, and advanced practice providers (APPs), such as oncology nurses, nurse practitioners, pharmacists, and physician assistants. Key expert faculty will discuss the therapeutic landscape in the 3L setting for patients specifically with refractory metastatic CRC. They will discuss pivotal clinical trials that have led to the approval of four different treatment regimens in this space, lack of guidance on sequencing strategies in the 3L, and what patient-specific factors and considerations they include in clinical decision-making for managing this challenging patient population of Veterans with mCRC.
TARGET AUDIENCE
This activity is designed to meet the educational needs of VA clinicians involved in the evaluation and management of veterans with mCRC including, but not limited to medical oncologists, gastroenterologists, and advanced practice providers (APPs), such as oncology nurses, nurse practitioners, pharmacists, and physician assistants.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the therapeutic potential and differentiate among available third-line (3L) treatment options for Veterans with metastatic colorectal cancer (mCRC)
- Leverage expert insight, real-world evidence (RWE), treatment histories, and patient-specific factors to inform optimal treatment selection and sequencing of 3L mCRC therapies
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Shubham Pant, MD | Dr. Pant discloses serving as a consultant for Zymeworks, Ipsen, Novartis, Janssen, Boehringer Ingelheim, AskGene Pharma, BPGBio, Jazz Pharmaceuticals, and AstraZeneca. He additionally receives research funding for clinical trials paid directly to The University of Texas MD Anderson Cancer Center from Mirati Therapeutics, Lilly, Xencor, Novartis, Bristol Myers Squibb, Astellas Pharma, Framewave, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics, Biotech, Pfizer and Telperian. He also discloses ownership interest in Telperian. |
| Benjamin Leon Musher, MD | Dr. Musher discloses receiving contracted research from LOKON Pharma and Merck & Co. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, Wolters Kluwer (UpToDate author royalties).
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Anita Misra-Press, PhD, Medical Director of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: December 17, 2024
EXPIRATION DATE: December 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.